Acute Gouty ArthritisPhase 3NCT01356602
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A Phase 3 study testing Canakinumab pre-filled syringe, Canakinumab lyophilized powder and Triamcinolone Acetonide in people with Acute Gouty Arthritis, run by Novartis Pharmaceuticals at 99 sites in 5 countries.
Trial summary
This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Acute Gouty Arthritis
- What is being tested?
- Canakinumab pre-filled syringe, Canakinumab lyophilized powder and Triamcinolone Acetonide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 397 participants
- Where
- 99 sitesin 5 countries
- Study dates
- May 2011to Sep 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 3 or more gout flares within last year
- Contraindication, intolerance or lack of efficacy for NSAIDs and/or colchicine
- Body mass index of less than or equal to 45 kg/m2
Who cannot join
- Use of the following therapies (within varying protocol defined timeframes): corticosteroids, narcotics, topical ice/cold packs, chronic opiate treatment, NSAIDs (such as aspirin), colchicine.
- Hemodialysis
- Live vaccine within 3 months before first dose
- Donation or loss of 400 mL or more within 3 months before first dose
- Gout brought on by other factors such as chemotherapy, lead, transplant, etc.
- Presence of other acute inflammatory arthritis such as Rheumatoid Arthritis
Show all 12Show fewer
- Any conditions or significant medical problems that puts the patient at an unacceptable immunological risk to receive this type of therapy such as HIV, Hepatitis, Tuberculosis and other infections/conditions
- Significant cardiovascular conditions such as uncontrolled hypertension
- Significant medical diseases such as uncontrolled diabetes, thyroid disease
- History of malignancy of any organ system within the past 5 years
- Women who are pregnant or nursing
- Other protocol-defined inclusion/exclusion criteria may apply
Trial locations and contacts
99 sites in 5 countries.
99 sites in 5 countries
United States69 sites
Novartis Investigative Site
Anniston, Alabama, 36207-5710
Novartis Investigative Site
Asheville, North Carolina, 28801
Novartis Investigative Site
Augusta, Georgia, 30904
Novartis Investigative Site
Bedford, Texas, 76021
Novartis Investigative Site
Bellevue, Washington, 98004
Novartis Investigative Site
Belzoni, Mississippi, 39038
Novartis Investigative Site
Bountiful, Utah, 84010
Novartis Investigative Site
Bristol, Tennessee, 37620
Novartis Investigative Site
Buena Park, California, 90620
Novartis Investigative Site
Cary, North Carolina, 27518
Novartis Investigative Site
Chandler, Arizona, 85224
Novartis Investigative Site
Charleston, South Carolina, 29412
Novartis Investigative Site
Charlotte, North Carolina, 28209
Novartis Investigative Site
Charlotte, North Carolina, 28277
Novartis Investigative Site
Charlottesville, Virginia, 22911
Novartis Investigative Site
Clearwater, Florida, 33756
Novartis Investigative Site
Columbia, South Carolina, 29204
Novartis Investigative Site
Dallas, Texas, 75231
Novartis Investigative Site
Danville, Virginia, 24541
Novartis Investigative Site
Decatur, Georgia, 30035
Novartis Investigative Site
Duncansville, Pennsylvania, 16635
Novartis Investigative Site
Fair Oaks, California, 95628
Novartis Investigative Site
Fargo, North Dakota, 58103
Novartis Investigative Site
Fayetteville, Tennessee, 33734
Novartis Investigative Site
Freehold, New Jersey, 07728
Novartis Investigative Site
Greensboro, North Carolina, 27401
Novartis Investigative Site
Greensboro, North Carolina, 27408
Novartis Investigative Site
Greer, South Carolina, 29651
Novartis Investigative Site
Gulf Shores, Alabama, 36547
Novartis Investigative Site
Houston, Texas, 77034
Novartis Investigative Site
Jackson, Mississippi, 39202
Novartis Investigative Site
Jackson, Mississippi, 39209
Novartis Investigative Site
Johnson City, Tennessee, 37601
Novartis Investigative Site
Jupiter, Florida, 33458
Novartis Investigative Site
Largo, Florida, 33773
Novartis Investigative Site
Lincoln, Nebraska, 68516
Novartis Investigative Site
Louisville, Kentucky, 40217
Novartis Investigative Site
Memphis, Tennessee, 38125
Novartis Investigative Site
Meridian, Idaho, 83642
Novartis Investigative Site
Metairie, Louisiana, 70006
Novartis Investigative Site
Midlothian, Virginia, 23114
Novartis Investigative Site
Mineola, New York, 11501
Novartis Investigative Site
Missoula, Montana, 59804
Novartis Investigative Site
Mobile, Alabama, 36608
Novartis Investigative Site
Mogadore, Ohio, 44260
Novartis Investigative Site
Murrells Inlet, South Carolina, 29576
Novartis Investigative Site
New Hyde Park, New York, 11042
Novartis Investigative Site
Newport News, Virginia, 23606
Novartis Investigative Site
Ninety Six, South Carolina, 29666
Novartis Investigative Site
Norwalk, California, 90650
Novartis Investigative Site
Oklahoma City, Oklahoma, 73109
Novartis Investigative Site
Omaha, Nebraska, 68114
Novartis Investigative Site
Omaha, Nebraska, 68134
Novartis Investigative Site
Orangevale, California, 95662
Novartis Investigative Site
Overland Park, Kansas, 66215
Novartis Investigative Site
Owensboro, Kentucky, 42303
Novartis Investigative Site
Pasadena, California, 91105
Novartis Investigative Site
Phoenix, Arizona, 85013
Novartis Investigative Site
Picayune, Mississippi, 39466
Novartis Investigative Site
Roslyn, New York, 11576
Novartis Investigative Site
Salisbury, North Carolina, 28144
Novartis Investigative Site
Scottsdale, Arizona, 85251
Novartis Investigative Site
Shelby, North Carolina, 28152
Novartis Investigative Site
South Miami, Florida, 33143
Novartis Investigative Site
Topeka, Kansas, 66606
Novartis Investigative Site
Troy, Michigan, 48085
Novartis Investigative Site
Varnville, South Carolina, 29944
Novartis Investigative Site
Westlake Village, California, 91361
Novartis Investigative Site
Wilmington, North Carolina, 28401
Hungary10 sites
Novartis Investigative Site
Békéscsaba, H-5600
Novartis Investigative Site
Budapest, 1023
Novartis Investigative Site
Budapest, 1027
Novartis Investigative Site
Debrecen, 4032
Novartis Investigative Site
Eger, 3300
Novartis Investigative Site
Gyula, 5703
Novartis Investigative Site
Kistarcsa, 2143
Novartis Investigative Site
Szikszó, Hungary, 3800
Novartis Investigative Site
Szolnok, 5000
Novartis Investigative Site
Veszprém, H-8200
Germany9 sites
Novartis Investigative Site
Bad Doberan, 18209
Novartis Investigative Site
Bayreuth, 95445
Novartis Investigative Site
Berlin, 13125
Novartis Investigative Site
Löhne, 32584
Novartis Investigative Site
Magdeburg, 39110
Novartis Investigative Site
Messkirch, 88605
Novartis Investigative Site
Regensburg, 93053
Novartis Investigative Site
Weener, 26826
Novartis Investigative Site
Zwiesel, 94227
Lithuania6 sites
Novartis Investigative Site
Kaunas, LT, 50128
Novartis Investigative Site
Kaunas, LT, 51349
Novartis Investigative Site
Klaipėda, 92288
Novartis Investigative Site
Vilnius, LT, 01117
Novartis Investigative Site
Vilnius, 09020
Novartis Investigative Site
Vilnius, LT-08661
Canada5 sites
Novartis Investigative Site
Sainte-Foy, Quebec, G1v 3M7
Novartis Investigative Site
Saskatoon, Saskatchewan, S7K 0H6
Novartis Investigative Site
St. John's, Newfoundland and Labrador, A1B 5E8
Novartis Investigative Site
St. John's, Newfoundland and Labrador, A1E 2C2
Novartis Investigative Site
Toronto, Ontario, M9W 4L6
About this study
Official title: A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.
- Conditions
- Acute Gouty Arthritis
- Being tested
- Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
- Keywords
- Gout, arthritis, gout flare, acute gout, gouty, rheumatic disease, uric acid
- Medical subject headings
- Gout, Arthritis, Rheumatic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Canakinumab pre-filled syringeDrug
Canakinumab pre-filled syringe
Canakinumab lyophilized powderDrug
Canakinumab lyophilized powder
Triamcinolone AcetonideDrug
Triamcinolone Acetonide
PlaceboDrug
Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
| Study group | Role | What they receive |
|---|---|---|
| Canakinumab, pre-filled syringes (PFS) | Experimental | Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug. Receives: Drug: Canakinumab pre-filled syringe; Drug: Placebo |
| Canakinumab, lyophilizate (LYO) | Active comparator | The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug. Receives: Drug: Canakinumab lyophilized powder; Drug: Placebo |
| Triamcinolone Acetonide | Active comparator | The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug. Receives: Drug: Triamcinolone Acetonide; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups
The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Missing pain intensity data at 72 hours was imputed using the Last-Observation-Carried-Forward (LOCF) method.
Measured: 72 hours post dose
Secondary outcomes (17)
Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups
The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Missing pain intensity data at 72 hours was imputed using the Last-Observation-Carried-Forward (LOCF) method.
Measured: 72 hours post dose
Patient's Assessment of Pain Intensity on a 0-100mm VAS
The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. The LOCF method was used to impute post-dose pain intensity VAS measurements up to 14 days.
Measured: 14 days
Patient's Assessment of Pain Intensity on a 5-point Likert Scale
A Likert scale is a type of scale with a range of responses corresponding to an item such as pain. The respondent selects the best response that indicates the respondent's subjective evaluation of the item. Patients scored their pain intensity in the most affected joint of the gout flare on a 5-point Likert scale (none, mild, moderate, severe, extreme). The scores were measured to the nearest millimeter from the left. The LOCF method was used to impute post-dose pain intensity Likert measurements up to 14 days.
Measured: 72 hours
Number of Patients With at Least One New Gouty Arthritis Flare After Baseline
Patients met the definition of a new flare if they had: a flare in a joint, which was not a previously affected joint (at baseline or during the study), or a flare in a joint previously affected (at baseline or during the study) after the previous flare in that joint had resolved completely according to the patient's perception. Patients did NOT meet the criterion of having a new gout flare if they had increasing/renewed gout pain in an affected joint before the flare had resolved completely.
Measured: 12 weeks
Time to the First New Gouty Arthritis Flare
Patients met the definition of a new flare if they had: a flare in a joint, which was not a previously affected joint (at baseline or during the study), or a flare in a joint previously affected (at baseline or during the study) after the previous flare in that joint had resolved completely according to the patient's perception. Patients did NOT meet the criterion of having a new gout flare if they had increasing/renewed gout pain in an affected joint before the flare had resolved completely. Less than 50% of patients had new flares. Therefore, the median time to new flare could not be calculated.
Measured: 12 weeks
Time to 50% Reduction in Baseline Pain on a 0 - 100 VAS
The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Kaplan Meier estimate of time to 50% reduction in baseline pain, along with associated 95% confidence interval, were reported.
Measured: 14 days
Time to Resolution of Gouty Arthritis Flare as Reported by Patient
Patients completed diary entries at 6, 12, 24, 48 and 72 hours post dose and then daily up to 7 days post-dose and/or daily until resolution of the flare. Kaplan Meier estimate of time to resolution of gouty flare as reported by patient, along with associated 95% confiedence interval, were reported.
Measured: 14 days
Patient's Global Assessment of Response to Treatment on a 5-point Likert Scale
A Likert scale is a type of scale with a range of responses corresponding to an item such as pain. The respondent selects the best response that indicates the respondent's subjective evaluation of the item. Patients scored their response to treatment on a 5-point Likert scale (excellent, good, acceptable, slight, poor). This outcome measure shows the number of patients indicating each score on the scale.
Measured: 72 hours
Physician's Global Assessment of Response to Treatment on a 5 Point Likert Scale
A Likert scale is a type of scale with a range of responses corresponding to an item such as pain. The respondent selects the best response that indicates the respondent's subjective evaluation of the item. Study physicians scored their assessment of the patients' response to treatment on a 5-point Likert scale (very good, good, fair, poor, very poor).
Measured: 72 hours
Physician's Assessment of Tenderness
The study physician assessed the most affected joint for tenderness. Tenderness was measured on a 0 - 3 point scale as follows: 0 = no pain, 1 = patient states that "there is pain", 2 = patient states "there is pain and winces" and 3 = patient states "there is pain, winces and withdraws" on palpation or passive movement of the affected study joint.
Measured: 72 hours
Physician's Assessment of Swelling
The study physician assessed the most affected joint for swelling. Swelling was measured on a 0 - 3 point scale as follows: 0 = no swelling, 1 = palpable, 2= visible and 3 = bulging beyond the joint margins.
Measured: 72 hours
Physician's Assessment of Erythema
The study physician assessed the most affected joint for erythema. Erythema was assessed as present, absent or not assessable.
Measured: 72 hours
Physician's Assessment of Range of Motion of the Most Affected Joint
The study physician assessed the patient's range of motion of the most affected joint on a 5 point Likert scale (normal, mildly restricted, moderately restricted, severely restricted and immobilized).
Measured: 72 hours
Proportion of Patients With Rescue Medication Intake
Patients used a diary to record the time of intake of rescue medication and the amount taken.
Measured: 12 weeks
Time to First Rescue Medication Intake
Patients used a diary to record the time of intake of rescue medication and the amount taken.
Measured: 14 days
Amount of Rescue Medication Taken (mg)
Patients used a diary to record the time of intake of rescue medication and the amount taken.
Measured: 14 days
C-reactive Protein Level
A central laboratory was used for analysis of all blood samples collected.
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2011 (estimated)
- Study startMay 2011
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Acute Gouty ArthritisStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 397 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01356602
- Sponsor's protocol ID
- CACZ885H2361
- Other IDs
- 2010-024173-39
- Status last verified
- Dec 2013
- First submitted
- 16 May 2011
- Last updated
- 29 Jan 2014
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
- ClinicalTrials.gov ID
- NCT01356602
- Acronym / sponsor ID
- CACZ885H2361
- Conditions
- Acute Gouty Arthritis
- Keywords
- Gout, arthritis, gout flare, acute gout, gouty, rheumatic disease, uric acid
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 397 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- May 2011
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 19 May 2011 (estimated)
- Results
- Posted 29 Jan 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Canakinumab, pre-filled syringes (PFS) | Experimental | Drug: Canakinumab pre-filled syringe, Drug: PlaceboPatients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug. |
| Canakinumab, lyophilizate (LYO) | Active comparator | Drug: Canakinumab lyophilized powder, Drug: PlaceboThe patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug. |
| Triamcinolone Acetonide | Active comparator | Drug: Triamcinolone Acetonide, Drug: PlaceboThe patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 3 or more gout flares within last year
- Contraindication, intolerance or lack of efficacy for NSAIDs and/or colchicine
- Body mass index of less than or equal to 45 kg/m2
Key exclusion criteria (12 listed)
- Use of the following therapies (within varying protocol defined timeframes): corticosteroids, narcotics, topical ice/cold packs, chronic opiate treatment, NSAIDs (such as aspirin), colchicine.
- Hemodialysis
- Live vaccine within 3 months before first dose
- Donation or loss of 400 mL or more within 3 months before first dose
- Gout brought on by other factors such as chemotherapy, lead, transplant, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Canakinumab pre-filled syringeCanakinumab pre-filled syringe | Drug | Canakinumab, pre-filled syringes (PFS) |
| Canakinumab lyophilized powderCanakinumab lyophilized powder | Drug | Canakinumab, lyophilizate (LYO) |
| Triamcinolone AcetonideTriamcinolone Acetonide | Drug | Triamcinolone Acetonide |
| PlaceboMatching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide | Drug | Canakinumab, lyophilizate (LYO), Canakinumab, pre-filled syringes (PFS), Triamcinolone Acetonide |
Primary outcome
Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups
Time frame: 72 hours post dose
The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, patients scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Missing pain intensity data at 72 hours was imputed using the Last-Observation-Carried-Forward (LOCF) method.
17 secondary outcomes
Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups
Time frame: 72 hours post dose
Patient's Assessment of Pain Intensity on a 0-100mm VAS
Time frame: 14 days
Patient's Assessment of Pain Intensity on a 5-point Likert Scale
Time frame: 72 hours
Number of Patients With at Least One New Gouty Arthritis Flare After Baseline
Time frame: 12 weeks
Time to the First New Gouty Arthritis Flare
Time frame: 12 weeks
Time to 50% Reduction in Baseline Pain on a 0 - 100 VAS
Time frame: 14 days
Time to Resolution of Gouty Arthritis Flare as Reported by Patient
Time frame: 14 days
Patient's Global Assessment of Response to Treatment on a 5-point Likert Scale
Time frame: 72 hours
Physician's Global Assessment of Response to Treatment on a 5 Point Likert Scale
Time frame: 72 hours
Physician's Assessment of Tenderness
Time frame: 72 hours
Physician's Assessment of Swelling
Time frame: 72 hours
Physician's Assessment of Erythema
Time frame: 72 hours
Physician's Assessment of Range of Motion of the Most Affected Joint
Time frame: 72 hours
Proportion of Patients With Rescue Medication Intake
Time frame: 12 weeks
Time to First Rescue Medication Intake
Time frame: 14 days
Amount of Rescue Medication Taken (mg)
Time frame: 14 days
C-reactive Protein Level
Time frame: 72 hours
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Acute Gouty Arthritis
Not yet recruitingPhase 2
A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis
Acute Gouty Arthritis
RecruitingPhase 2
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
Acute Gouty Arthritis
RecruitingPhase 2
Clinical Study of HRS-2129 for Acute Gouty Arthritis
Acute Gouty Arthritis
Not yet recruitingPhase 2
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
Gout Arthritis
Not yet recruitingPhase 4
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time
Gout
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
99 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Canakinumab pre-filled syringe, Canakinumab lyophilized powder and Triamcinolone Acetonide in people with Acute Gouty Arthritis, run by Novartis Pharmaceuticals at 99 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 99 sites in United States, Hungary, Germany, Lithuania, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 29 Jan 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups (time frame: 72 hours post dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2014.